Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia.
Phase of Trial: Phase IV
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 09 Jan 2018 Planned End Date changed from 1 Jan 2017 to 1 Jan 2019.
- 09 Jan 2018 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2019.
- 10 Jun 2017 Biomarkers information updated